Navigation Links
BioMS Medical Announces 2008 Year End Results
Date:3/17/2009

Toronto Stock Exchange Symbol: MS

EDMONTON, March 17 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the year ended December 31, 2008.

"Dirucotide has demonstrated the ability to safely affect MS progression in previous studies and we look forward to the results of the Canadian/European trial (MAESTRO-01) in the second half of this year," said Kevin Giese, President and CEO of BioMS Medical. "Our hope is that the results of this trial will confirm that dirucotide is able to significantly slow the progression of MS, specifically in patients with secondary progressive multiple sclerosis."

Currently, BioMS is conducting two clinical trials and one open-label follow-on trial of dirucotide for the treatment of secondary progressive MS (SPMS):

        -  MAESTRO-01: On January 22, 2007, BioMS announced that this pivotal
           phase III trial, being conducted in Canada and Western Europe, had
           completed full recruitment of 611 SPMS patients at 47 trial sites
           in ten countries. To date, there have been nine positive safety
           reviews from the Data Safety Monitoring Board (DSMB). The primary
           clinical endpoint for MAESTRO-01 (and MAESTRO-03) is defined as a
           statistically and clinically significant increase in the time to
           progression of the disease as measured by the Expanded Disability
           Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4
           immune response genes.

           On August 13, 2008, the DSMB conducted a scheduled interim
           analysis of efficacy and safety and recommended that the trial
           continue to completion. The interim analysis evaluated the first
           200 patients to complete MAESTRO-01 and assessed the likelihood of
           the study reaching
'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. BioMS Medical warrant extension
2. BioMS Medical to present at BIO CEO and Investor Conference
3. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
4. BioMS Medical recognized at Scrip Awards 2008
5. BioMS Medical Announces Third Quarter 2008 Results
6. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
10. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
11. BioMS Medical to present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... (PRWEB) April 01, 2015 “Science can be ... and fifth-graders participated in an “Introduce a Girl to Engineering ... February. Lessons in light-based science and technology were presented by ... Student Chapters awarded a total of $60,000 in International ... international society for optics and photonics . The IYL grants ...
(Date:4/1/2015)... SEATTLE , April 1, 2015  Adaptive ... The Lancet Oncology showing ... the company,s next-generation sequencing-based minimal residual disease (MRD) ... clonoSEQ™ MRD test) accurately identifies patients with diffuse ... of relapse after initial treatment, usually several months ...
(Date:4/1/2015)... City, UT (PRWEB) April 01, 2015 ... agreement allowing Biosearch to make, use, market and ... agreement also licenses CoPrimers™ technology to Biosearch for ... patent-pending design greatly reduces the occurrence of primer-dimers, ... resulting in increased sensitivity and lower test prices. ...
(Date:4/1/2015)... Shimadzu Corporation announced that its ... system (Nexera UC) received the Pittcon Editors’ Gold ... Chemistry and Applied Spectroscopy (Pittcon) held in New ... , The Pittcon Editors’ Awards recognize the most ... time based on votes by the media corps. ...
Breaking Biology Technology:Fun, wonder, importance of light are messages in SPIE Student Chapter IYL2015 events 2Fun, wonder, importance of light are messages in SPIE Student Chapter IYL2015 events 3Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 2Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 3Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 4Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 5Biosearch and Co-Diagnostics Sign Cooperative Primers Agreement 2Biosearch and Co-Diagnostics Sign Cooperative Primers Agreement 3Shimadzu Nexera UC Recognized at Pittcon 2015 with Editors’ Gold Award 2
... ... ... 27, 2009 -- Global food security, which is increasingly being recognized as a key ... private partnerships, William S. Niebur , vice president – DuPont Crop Genetics Research ...
... Organovo, Inc., a regenerative medicine company focused on bioprinting ... M.B.A, to its board of directors. Baltera is the ... and has over 19 years of pharmaceutical and biotechnology ... of the life sciences industry will provide great value ...
... /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE: SVA ), ... that,it has received its third purchase order for its ... Technology for the national,stockpiling plan. Under this purchase order, ... of PANFLU.1 (15ug/0.5ml) for the Chinese central,government. Out of ...
Cached Biology Technology:Public-Private Partnerships Key to Achieving Global Food Security, Says DuPont Leader 2Public-Private Partnerships Key to Achieving Global Food Security, Says DuPont Leader 3Organovo Appoints Robert Baltera to Board 2Sinovac Obtains Third H1N1 Vaccine Order from Chinese Central Government 2Sinovac Obtains Third H1N1 Vaccine Order from Chinese Central Government 3
(Date:4/1/2015)... Conn. , Apr. 1, 2015  NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... of Wocket smart wallets is underway to early access ... access group includes usage at retail outlets including Walmart, ... Pharmacy. Users report Wocket was accepted at all outlets ...
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, ... million users across iOS and Android ... begun integrating biofeedback into the platform to allow patients ... outcomes. For the first time, patients will be able ... a dose impacts important biometrics, such as glucose levels ...
(Date:3/31/2015)... , March 31, 2015  Elephant Talk Communications ... a global provider of Software Defined Network Architecture (ET ... announced total revenue of approximately $20.4 million for the ... restated $19.5 million for the year ended December 31, ... 2014, the Company had completed its multi-year transition away ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... have been selected for awards from the Merck/AAAS ... Institute for Science Education (MISE) and the American ... program awards provide up to $60,000, paid over ... chemistry departments at the recipient institution. This ...
... SALT LAKE CITYUnraveling the genetics of social behavior and ... the Salk Institute for Biological Studies have traced the ... genetic disorder known as Williams Syndrome. Their ... of the American Journal of Medical Genetics , ...
... The genome of the evolutionary ancestor of humans and present-day ... DNA, according to a study to be published in ... birthday. "The new study shows big differences in ... containing rapidly evolving genes. Most of these differences occurred at ...
Cached Biology News:2 genes influence social behavior, visual-spatial performance in people with Williams syndrome 22 genes influence social behavior, visual-spatial performance in people with Williams syndrome 3Ancestral genome of present-day African great apes & humans had burst of DNA sequence duplication 2
Guanylate Kinase Purified Anti-Mouse, Anti-Rat clone 28, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
...
Proliferin (C-14)...
... submarine gel systems used gasketed gel trays. Turn the ... tank. Turn it back and run the gel - ... Turn & Cast tray is UV transparent. Each tray ... the tray and one in the center. This allows ...
Biology Products: